our science
Our lead programs
Eikonizo’s Platform Targets HDAC6
Eikonizo is developing brain-penetrant, small molecule, selective histone deacetylase 6 (HDAC6) inhibitors as disease-modifying therapeutics for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy (CIPN) and Alzheimer’s disease.
Eikonizo is also developing peripherally-restricted, small molecule, selective HDAC6 inhibitors for ADPKD and cardiac indications.
Therapeutic Hypothesis
Illustrations of how HDAC6 inhibitor treatment will preserve axonal transport and prevent tau aggregation to stop or slow the progression of ALS and AD
Supporting
Literature
Extensive data from multiple research groups support Eikonizo’s approach for using HDAC6 inhibitors as a disease-modifying therapeutic for neurodegeneration in ALS and AD